Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Update

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 50 shares, a decline of 99.8% from the May 14th total of 23,016 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 1,489 shares, the short-interest ratio is currently 0.0 days.

Innate Pharma Price Performance

Shares of OTCMKTS:IPHYF opened at $1.65 on Wednesday. The stock’s 50-day moving average is $1.64 and its 200-day moving average is $1.92. Innate Pharma has a 52-week low of $1.37 and a 52-week high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.